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Nuclear transport, phosphorylation, ligand binding, 
and degradation rate of the recombinant androgen 
receptor (AR) were analyzed in transfected COS cells 
in the presence of various  steroids  and antiandrogens. 
Transcriptional activition was assessed in CV1 cells by 
cotransfection with  an androgen-responsive chloram- 
phenicol acetyltransferase (CAT) reporter vector. Hor- 
mone binding specificity of recombinant AR was essen- 
tially identical to endogenous AR.  AR localized in  the 
nucleus in  the presence of methyltrienolone (R1881, a 
synthetic androgen), dihydrotestosterone, testoster- 
one, hydroxyflutamide, cyproterone  acetate,  estradiol, 
progesterone, and RU486. In the absence of hormone 
or with the antiandrogen, flutamide, AR remained 
largely in  the cytoplasm with a perinuclear  distribu- 
tion. AR was degraded rapidly (tl lz = 1 h) except in  the 
presence of androgen (t l lz  = 6 h) which accounted for 
an apparent 2-4-fold androgen-induced increase  in AR 
phosphorylation, indicating that AR phosphorylation 
was not enhanced by androgen. CAT activity  was tim- 
ulated by R1881, dihydrotestosterone, testosterone, 
cyproterone  acetate,  estradiol, progesterone, and 
RU486 in a dose-dependent manner. The antiandro- 
gens, flutamide and hydroxyflutamide, lacked agonist 
activity and inhibited R1881-induced activation of 
CAT and androgen stabilization of AR. Steroids and 
antiandrogens  with moderate to low affinity  for AR 
promoted both nuclear transport and transcriptional 
activation but only at high hormone concentrations. 
Hydroxyflutamide acted as a true antiandrogen since 
it lacked agonist activity  and was an  inhibitor of an- 
drogen-induced transcriptional activation. 
The biological effects of androgens can be inhibited by 
androgen antagonists known as antiandrogens.  On the basis 
of structure,  antiandrogens are subdivided into two groups, 
steroidal and nonsteroidal, both of which can  inhibit  agonist 
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binding to  the androgen receptor (AR)’ (1). Flutamide (LY,LY,(Y- 
trifluoro-2-methyl-4’-nitro-m-propionotoluidide) is consid- 
ered a pure  antiandrogen because it lacks agonist activity and 
is specific for the AR. Administered to animals, flutamide has 
potent antiandrogenic effects on male reproductive tissues, 
decreasing organ size (2, 3) and blocking androgen effects in 
castrated rats. It was postulated that since flutamide shows 
little binding affinity for AR, its effects in vivo are mediated 
through a hydroxylated metabolite, hydroxyflutamide ((Y,LY,LY- 
trifluoro-2-methyl-4’-nitro-rn-lactotoluidide) (4-7). Subse- 
quent studies  demonstrated that hydroxyflutamide adminis- 
tered in  vivo is an effective antiandrogen (8). More recently 
flutamide itself was shown to inhibit receptor binding of 
labeled androgen but only at very high concentrations (Ki 10 
W )  (9). 
RU486 is a synthetic progestin and glucocorticoid antago- 
nist  that binds with high affinity to glucocorticoid and pro- 
gesterone receptors (10, 11) and causes efficient nuclear lo- 
calization of these receptors (12-14).  RU486 promotes specific 
binding of progesterone (15-17) and glucocorticoid receptors 
(18) to  their hormone response elements, does not induce a 
transcriptional response (15), and blocks the constitutive 
transcriptional  function of a truncated  mutant form of the 
progesterone receptor (19). 
This report addresses the functional activity of transiently 
expressed AR when bound by antiandrogens and antigluco- 
corticoids in comparison with biologically active androgens, 
testosterone and dihydrotestosterone, and  the synthetic an- 
drogen, R1881. The hormone specificity of nuclear transport 
was investigated since previous studies demonstrated that 
R1881 promotes nuclear localization of  AR from the perinu- 
clear cytoplasmic region of transiently transfected COS cells 
(20). The effects of different steroids and antiandrogens  on 
AR protein  turnover and phosphorylation were investigated 
since studies  on other steroid receptors (21-24) and  the AR 
(25) provided evidence for hormone-dependent phosphoryla- 
tion. Finally, steroid hormone and antihormone  stimulation 
of AR-mediated transcriptional  activation was compared 
using a cotransfection assay in which R1881 promoted strong 
’ The abbreviations used  are: AR, androgen receptor; R1881, meth- 
yltrienolone; IgG, immunoglobulin G; CAT, chloramphenicol acetyl- 
transferase; flutamide, a-a-a-trifluoro-2-methyl-4’-nitro-n-propion- 
otoluidide, or 4’-nitro-3’-trifluoromethylisobutyr-anilide or SCH 
13521; hydroxyflutamide, a-a- a-trifluoro-2-methyl-4’-nitr0-m-lac- 
totoluidide or SCH 16423; cyproterone acetate, 6a-chloro-17a-hy- 
droxy-la,2~-methylene-4,6-pregnadiene-3,2O-dione-l7-acetate; 
RU486, Roussel Uclaf list no. 36,486, mifepristone, 11@-(4-dimethyl- 
aminophenyl)-l7~-hydroxy-17a-(prop-l-ynyl)-estra-4,9-diene-3-one; 
LNCaP, lymph node-derived human prostate cancinoma cell line; 
SDS, sodium dodecyl sulfate; HEPES, 4-(2-hydroxyethyl)-l-pipera- 
zineethanesulfonic acid. 
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induction of the chloramphenicol acetyltransferase gene 
linked to  an androgen-responsive promoter (26). 
EXPERIMENTAL PROCEDURES 
Materials-The following reagents were purchased monkey kidney 
COS-7 and CV1 cells from the American Type Culture Collection; 
Dulbecco’s  modified essential medium with high  glucose and Eagle’s 
modified essential medium without phosphate from GIBCO; bovine 
serum from HyClone Laboratories, Inc.; ~-threo-[1,2-C’~]chloram- 
phenicol, 40-60 mCi/mmol and  Tran~~~S-label  (L-methionine, [Y3], 
L-cysteine, [%3]), 1000 Ci/mmol from ICN Biomedicals, Inc.; phos- 
phorus 32-orthophosphoric acid from Du Pont; acetyl coenzyme A 
and DEAE-dextran from Pharmacia  LKB Biotechnology Inc.; [3H] 
methyltrienolone ([17~~-methyl-~H]R1881, 0 Ci/mmol) from Du 
Pont-New England Nuclear; W-OMAT-AR diagnostic x-ray film and 
thin layer silica gel chromagram sheets from Kodak; buffers and 
chemicals from Fisher, EM Science, and Sigma. 
Cell Transfection-Nuclear transport, receptor turnover, and phos- 
phorylation were determined in monkey kidney COS-7 cells trans- 
fected with 10 pg of the full-length human AR expression vector 
pCMVhAR (p5HBhAR-A) (20, 26) using DEAE-dextran (27). COS 
cells were maintained in  10% fetal calf serum in Dulbecco’s minimal 
essential medium containing high glucose and antibiotics and plated 
a t  1.0 X lo6 cells/lO-cm dish. Immediately after transfection cells 
were placed in 5% serum containing medium, and 24 h later, into 
serum-free, phenol red-free medium in the presence or absence of 
hormone. For immunocytochemical studies, COS cells were trans- 
fected on two chamber glass slides as previously described (20). 
Twenty-four h prior to fixation, cells were placed in serum-free, 
phenol red-free medium in the presence or absence of steroid. Medium 
with or without hormone was replaced with fresh medium 2  h prior 
to fixation. Transfection efficiency ranged from 4-8% as reflected by 
AR immunostaining of transiently  transfected COS  cells. The level 
of  AR expression in COS cells was 340 +- 22 fmol/mg protein, 
determined in a whole  cell binding assay described below. 
AR functional activity was assessed in monkey kidney CVI cells 
by transient  transfection as previously described (20). CV1 cells were 
maintained in 10% fetal calf serum in medium as described above. 
Cells were plated at 1.3 X lo6 cells/lO-cm dish so that approximately 
80-90% confluence was achieved at  the time of transfection 24 h 
later. Cells were transfected with 1-3 pg of AR expression vector 
pCMVhAR and 1-3 pg of the reporter vector using the calcium 
phosphate DNA precipitation method (27). The CAT reporter vector 
pMTV29VTM contains two glucocorticoid response elements sepa- 
rated by 29 base pairs and positioned 5’ of the CAT gene (28). AR 
expression in CV1 cells was 30 +- 10 fmol/mg protein determined in 
the whole  cell binding assay and was  below the detection level by  AR 
immunocytochemistry. CAT assays representative of at least six 
than 100-fold. 
independent experiments are shown with maximal induction greater 
Binding Specificity-Steroid and nonsteroidal antiandrogen bind- 
ing specificities were determined in COS cells transiently expressing 
recombinant AR using a whole cell binding assay previously described 
(27). COS cells in 24-well tissue culture  plates  containing lo5 cells/ 
well  were transfected with 1 pg  of pCMVhAR  DNA/well using DEAE- 
dextran (27). Cells  were maintained for 24 h in Dulbecco’s  modified 
Eagle’s medium containing 5% fetal calf serum until 24 h prior to 
labeling when they were placed in serum-free, phenol red-free media. 
Cells were labeled for 2  h with 5 nM [3H]methyltrienolone (R1881) 
in  the presence or absence of increasing concentrations of unlabeled 
hormones. Nonspecific binding was accounted for by parallel incu- 
bations in the presence of a 100-fold excess unlabeled R1881. Labeling 
medium was removed and the cells washed twice in phosphate- 
buffered saline and harvested in 2% SDS,  10% glycerol, and 10 mM 
Tris, pH 6.8, and radioactivity determined by scintillation counting. 
Immunocytochemistry-COS cells transfected with pCMVhAR 
DNA  were stained using the immunoglobulin G (IgG) fraction of a 
rabbit polyclonal AR specific, anti-peptide antibody AR52 (26, 29). 
The staining procedure was previously described (20,30)  and utilized 
biotinylated goat anti-rabbit IgG (1:800) and  the avidin biotin per- 
oxidase (1:400) from Vector Labs, Inc., Burlingame, CA (31). 
Receptor Turnover and Phosphorylation-Phosphorylation and 
turnover studies were performed using methodology similar to  that 
previously described (32). Forty-eight h  after COS  cell transfection 
with pCMVhAR, serum-free, phenol red-free medium was aspirated 
and the cells washed with 3 ml of either phosphate-free Eagle’s 
minimal essential medium containing 20 mM HEPES, pH 7.2, or 
methionine-free Eagle’s minimal essential medium containing 20 mM 
HEPES,  pH 7.2. Four ml  of fresh phosphate-free or methionine-free 
media was added, and  the cells were incubated at 37 “C in  a 5%  Con 
incubator for 15 min. Steroids or nonsteroidal antiandrogens and 200 
pCi of [32P]orthophosphate or 200 pCi of Tran~~~S- labe l  were added 
and incubated for the indicated times at 37 ‘C. Cells were washed 
twice with Dulbecco’s  modified  Eagle’s  media and harvested by scrap- 
ing into 1 ml of RIPA buffer (1% Triton X-100, 1% deoxycholate, 
0.1% sodium dodecyl sulfate, 0.15 M NaCl, 0.5 mM sodium vanadate, 
5 mM EDTA, and 50 mM Tris, pH 7.4).  DNA  was heared by repeated 
passage through  a  Pasteur  pipette and  the samples rotated for 20 min 
at 4 “C. Supernatants of a 15-min centrifugation at 13,000 X g a t  4 ”C 
were transferred to new  microfuge tubes and 60 pg  of  AR52  AR anti- 
peptide IgG (26,29) added and incubated overnight a t  4 “C. Pansorbin 
Staphylococcus aureus cells (Calbiochem Corp., La Jolla, CA) were 
prepared fresh by washing with six volumes of 10% SDS followed  by 
three washes with RIPA with 1-min centrifugations to pellet the cells. 
The final  Pansorbin pellet was resuspended in an equal volume of 
RIPA and 20 pl added to each sample followed by incubation for 2 h 
a t  4 “C. After a  1-min centrifugation, a series of 0.3-ml  washes of the 
pellets with 30 s centrifugations included twice RIPA; 0.5 M NaC1, 
RIPA; 1 mg/ml bovine serum albumin, RIPA; 0.5 M NaCl, RIPA; 1 
mg/ml  bovine serum albumin, RIPA; twice RIPA. The final pellets 
were resuspended in 75  pl  of  2.5% SDS, 12.5% glycerol, 12.5 mM Tris, 
pH 6.8, and incubated at room temperature for 10 min. Following a 
2-min centrifugation, the supernatants were transferred to new tubes 
and made 4% 2-mercaptoethanol and 0.05% bromphenol blue. Sam- 
ples were heated at 95 “C for 5 min, cooled to room temperature,  and 
loaded onto 8% SDS-polyacrylamide gels prepared as described (27, 
33). The extent of radiolabel incorporation was determined by com- 
puter analysis of the transferred membranes on an Ambis radioscan- 
ner. The  data shown are representative of at least three independent 
experiments. 
RESULTS 
Recombinant AR Steroid Binding Specificity-In a whole 
cell competitive binding assay, transiently expressed AR had 
highest apparent binding affinity for R1881, followed by di- 
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FIG. 1. Steroid binding affinity of recombinant AR ex- 
pressed  in COS cells. A whole  cell binding assay was performed as 
previously described with minor modifications (27). Twenty-four- 
multiwell tissue culture dishes containing approximately 1 X lo5 
cells/well  were transfected with pCMVhAR using 1 pg  of expression 
vector DNA as described under “Experimental Procedures.” Forty- 
eight h  after  transfection, cells were incubated for 2  h with 5 nM [3H] 
R1881 in the absence or presence of 1-, lo-,  and 100-fold molar excess 
unlabeled steroids as indicated. Binding is expressed as the percent 
of [3H]R1881 bound after  subtraction of nonspecific binding deter- 
mined in the presence of a 100-fold molar excess of  R1881. Data  are 
indicated for R1881 (O), dihydrotestosterone (DHT, 0), cyproterone 
acetate (CA, 0), RU486 (A), estradiol (A), hydroxyflutamide (OH- 
flutarnide, El), and flutamide (.) Binding data not shown included 
testosterone and progesterone inhibition curves which were similar 
to dihydrotestosterone and estradiol, respectively. 
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was similar to dihydrotestosterone. Cyproterone acetate, es- 
tradiol (Fig. l), and progesterone (not shown) compete for 
['H]R1881 bindingwith 6040% inhibition at  a 100-fold molar 
excess of unlabeled hormone (Fig. 1). The antiandrogen flu- 
tamide failed to inhibit binding of [3H]R1881 in this concen- 
tration range as previously reported for the endogenous recep- 
tor (9)) and hydroxyflutamide inhibited binding by about 50% 
at a 100-fold molar excess concentration (Fig. 1). RU486, a 
glucocorticoid and progesterone receptor antagonist (10, l l ) ,  
inhibited binding by about 70% at a 100-fold molar excess of 
labeled hormone (Fig. 1). Thus, the binding specificity of 
recombinant AR expressed in COS cells was similar to  that 
of the endogenous receptor (34-36) in its limited specificity 
a t  elevated steroid  concentrations. Both endogenous and  tran- 
siently expressed AR bind  a  variety of steroid  hormones and 
antagonists with apparent moderate  affinities (lo-' K J .  How 
this binding effects receptor function was examined by analy- 
sis of  AR nuclear localization, degradation rate, phosphoryl- 
ation,  and transcriptional activition. 
Hormone Specificity of  AR Nuclear Transport-Androgen- 
dependent transport of AR to the nucleus was previously 
demonstrated  in transiently transfected COS cells (20) and is 
shown in Fig. 2, A-C. In the absence of hormone, AR is 
localized in the perinuclear region of the cytoplasm (Fig. 2 A ) .  
Nuclear localization of  AR was observed following incubations 
with 50 nM R1881 (B), dihydrotestosterone (C), or testoster- 
one  (not shown), or 100 nM hydroxyflutamide ( E ) ,  cyproter- 
one acetate ( F ) ,  RU486 ( G ) ,  estradiol (H), and progesterone 
( I ) .  Hormone concentrations less than 50 nM resulted in the 
presence of both nuclear and perinuclear  staining, suggesting 
that receptors were not  saturated at  the lower hormone  con- 
centrations. Thus nuclear localization of AR in transfected 
COS cells occurred with a variety of steroids and  antiandro- 
gens. AR immunostaining  in the presence of 100 nM flutam- 
ide, however,  was predominantly  perinuclear  in the cytoplasm 
with only minimal nuclear staining (D). 
Receptor Phosphorylation and Turnover-Steroid effects on 
. 1 ~. . " 
AR phosphorylation were investigated by incubating trans- 
fected COS cells with [R2P]orthophosphate and immunopre- 
cipitating receptor using anti-peptide AR antibody AR52 de- 
scribed previously (29).  Transfection with the  parent expres- 
sion vector (P5) which lacks AR coding sequence produced 
no major phosphorylated products (Fig. 3A, lane 1 ). In the 
absence of hormone, AR was detected as  a 114-kDa phospho- 
protein (Fig. 3A, lune 2). Addition of R1881, dihydrotestos- 
terone, or testosterone at  5-50 nM appeared to  stimulate the 
incorporation of radiolabeled phosphate 2-4-fold  following a 
3-h incubation  (lanes 3-5).  AR phosphorylation was not sig- 
nificantly enhanced by treatment with 100 nM estradiol, 
progesterone, or the antiandrogens, cyproterone acetate, flu- 
tamide, or hydroxyflutamide (lunes 6-10). However, 100 nM 
RU486 caused an  apparent increase in AR phosphorylation 
(lune 11 ) similar to  that observed with androgens. None of 
the hormones  altered basal receptor phosphorylation observed 
in the absence of androgen. Treatment with 100 nM R1881 
20 min prior to harvest showed a 1.5-fold increase in apparent 
phosphorylation (lane 13), but no increase was observed when 
R1881 was added to  the harvest buffer (lane 14). Thus  the 
steroid requirements for hormone-induced phosphorylation 
appeared to be androgen specific with the exception of  RU486. 
We investigated whether the  apparent increase in AR phos- 
phorylation described above resulted from androgen-en- 
hanced AR immunoreactivity or receptor stabilization. Par- 
allel incubations were performed with "S-labeled methionine 
and cysteine for 3- or 24-h labeling periods in  the presence 
and absence of 10 nM androgens or 100 nM nonandrogenic 
steroids or antiandrogens. Androgens specifically increased 
3-5-fold the amount of "S-labeled receptor (Fig. 3B), which 
was slightly greater than  the  apparent increase in receptor 
phosphorylation observed in Fig.  3A. Steroids and antiandro- 
gens which did not enhance phosphorylation also did not 
increase "S-labeled AR. A 20-min exposure to androgen or 
androgen addition to  the harvest medium (Fig. 3B, lanes 13 
and 14) yielded a pattern similar to the phosphorylation 
FIG. 2. Immunocytochemical localization of AR in the absence or presence of steroids  and  antian- 
drogens. The pCMVhAR expression vector was transfected into COS cells using DEAE-dextran as described. 
Twenty-four h after transfection the  cells were placed in serum-free, phenol red-free media in the absence ( A )  or 
presence of 50 nM R1881 ( B ) ,  dihydrotestosterone (C), 100 nM flutamide (D), hydroxyflutamide ( E ) ,  cyproterone 
acetate (F), RU486 ( G ) ,  estradiol-17P (H), or progesterone ( I ) .  Twenty-four h later and 2 h before fixation, steroid 
containing media were  replaced with fresh identical media. The slides were washed, fixed, and stained with the 
avidin biotin peroxidase method as previously described (30, 31). Magnification X 230. 
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FIG. 3. A and E ,  specificity of hormone-induced AR phosphoryl- 
ation  and  stabilization. COS  cells transfected  with  the full-length  AR 
expression vector or  parent  pCMV5 vector  were incubated  with  either 
200 pCi of [32P]orthophosphate for 3 h ( A )  or 24 h with Trans3'S- 
label ( E )  prior  to cell harvest  and washing. The 114-kDa  AR protein 
was immunoprecipitated using AR52 anti-peptide IgG fraction as 
described under "Experimental Procedures." The labeling periods 
were in serum-free, phosphate-free media containing  the radiolabel 
with no addition of hormone (lane 2 ) ,  or  addition of 10 nM R1881 
(lane 3 ) ,  dihydrotestosterone (DHT, lane 4 ) ,  testosterone ( T ,  lune 5), 
or 100 nM estradiol ( E ,  lune 6 ) ,  progesterone (P ,  lane 7), cyproterone 
acetate (CA, lane 8) ,  flutamide (FL, lane 9), hydroxyflutamide (OH- 
FL, lane IO), or RU486 (RU, lane 11). Lune 1 contains  an  immune 
extract from cells transfected with the parent pCMV expression 
vector (P5)  which lacks AR  coding  sequence. 
results. Thus,  the  apparent androgen-stimulated  increase in 
AR phosphorylation appeared to be due to a  parallel increase 
in AR protein. Sodium dodecyl sulfate-gel electrophoresis and 
immunoblot analysis of  AR in whole cell extracts  not immu- 
noprecipitated (not shown) indicated that preferential im- 
munoprecipitation of the androgen-bound receptor did not 
occur. 
The hormone dependence of receptor turnover was exam- 
ined in a pulse-chase experiment. Following a 30-min incu- 
bation with 200 pCi of [35S]methionine, cells in monolayer 
culture were incubated  in the presence or absence of 100 nM 
R1881, harvested at  increasing time  intervals, and subjected 
to immunoprecipitation and SDS-gel electrophoresis. As 
shown in Fig. 4, a major decrease in the rate of receptor 
degradation occurred in the presence of androgen. AR de- 
graded intracellularly at  37 "C with a  half-time of approxi- 
mately 1 h  in the absence of androgen and 6 h  in the presence 
of androgen (Fig. 4, A and B ) .  Nonandrogenic steroids in- 
cluded in this study had little or no effect on the degradation 
rate observed in the absence of androgen (not shown). The 
antiandrogens, hydroxyflutamide and cyproterone  acetate,  in- 
hibited androgen-induced stabilization when included a t  a 
100-fold molar excess. I t  is concluded that  the &fold enhance- 
ment of receptor stability by androgen binding could account 
for the  apparent androgen-stimulated increase in AR phos- 
phorylation, and therefore, androgen does not promote recep- 
tor phosphorylation in this assay system. 
TranscriptionalActiuation-Transient cotransfection of the 
AR expression plasmid with  a CAT reporter vector in CV1 
cells was performed to determine  whether other steroids and 
antiandrogens that bind the receptor stimulate AR-mediated 
gene transcription. R1881, dihydrotestosterone, and testos- 
terone each induced CAT activity in a  dose-dependent  man- 
ner between 0.001-1 nM (Fig. 5 ) .  Low basal activity was 
observed with the  parent pCMV expression vector (P5) with 
or without 10 nM R1881 or with the AR expression vector in 
the absence of hormone (Figs. 5 and 6). Estradiol and proges- 
terone  stimulated CAT activity nearly equal to  that of andro- 
gen but only at  1000-fold higher hormone Concentrations (Fig. 
5 ) .  Estradiol (1 nM) and progesterone (10 nM) produced a 
transcriptional response similar to  that of 0.001 nM R1881 
(Fig. 5 )  but were inactive at  0.001  nM. At 10 nM estradiol or 
100 nM progesterone, CAT activity was equivalent to  that 
induced by 0.01 nM R1881 (Fig. 5) .  
CAT activity induced by  100 nM cyproterone acetate  or 100 
nM RU486  was approximately 50 and 15-20%, respectively, 
. ( . I  I 
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FIG. 4. Stability  of AR in transfected COS cells in the pres- 
ence and absence of androgen. A, stability  studies  on  the  tran- 
siently expressed AR in COS were performed as described under 
"Experimental Procedures" and in Fig. 3 legend. After the 30-min 
pulse incubation  with 200 pCi of Trans'"S-labe1, cells were transferred 
to serum-free media with  or  without 100 nM R1881 and harvested a t  
0.5,1,2,4,  and 6 h of incubation a t  37 "C as indicated. E ,  inactivation 
kinetics of the  androgen-bound  and free AR. Computer  analysis of 
the  transblots  shown  in A was determined  on  an Ambis radioscanner 
to yield the  data shown. The t l , z  of AR degradation was 1 h in the 
absence of androgen  and 6  h in  the presence of 100 nM R1881. 
FIG. 5. Hormone specificity of transcriptional activation by 
the AR. CAT  activity was  measured in CV1 cells as described under 
"Experimental Procedures."  After transfection  the cells were placed 
in 0.2% serum-containing media with  the  addition of the indicated 
concentrations of R1881, dihydrotestosterone (DHT), testosterone 
(T), estradiol ( E s t ) ,  and  progesterone (Prog) .  The acetylated  forms 
of [14C]chloramphenicol were separated by thin layer  chromatogra- 
phy. The fold induction of activity  shown below was  calculated by 
eluting  the radioactivity from  the  thin layer plates  and  determining 
the  counts by scintillation counting. 
of that observed with 0.01 nM R1881 (Fig. 6). In a control 
study not shown, RU486 failed to induce CAT activity when 
the full-length glucocorticoid receptor was coexpressed in CV1 
cells. No significant AR-induced CAT activity was detected 
following incubations  with flutamide or hydroxyflutamide at  
concentrations up  to 100 nM (Fig. 6). 
Thus, transcriptional  activation by  AR was androgen spe- 
cific only at  hormone concentrations less than 1 nM. A t  higher 
concentrations,  induction of CAT activity reflected AR bind- 
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FIG. 6. Transcriptional CAT ac- 
tivation following incubation with 
androgen,  antiandrogens, and 
RU486. CAT activity was determined 
in CV1 cells transfected with the full- 
length  uman pCMVhAR  expression 
vector. Immediately after transfection, 
cells were placed in 0.2% fetal calf - 10 - 1 i o  i o 0  1 10 100 1 10 100 1 10 100 (nM) 
serum-containing media plus the addi- 
tion of hormones as indicated. The  first 
two  lanes  represent  the  parent P5 vector 
lacking AR sequence and  the  remaining 
lanes  are  the  full-length expressed AR. loo- 
Fold induction of activity is indicated as = 80 
a bar graph below and was determined 2 
- 
by  scintillation  counting  the  luted ra- 6o 
- 
dioactivity. - 4 0 -  
O.O1 1 1  1”- 
R1881 Cyproterone  Flutamide  OH-flutamide RU486 - Acetate 
P5 
2 20-  
0 
I I I 
ing affinity. An exception was hydroxyflutamide, which dis- 
played binding to AR (Fig. l) ,  caused nuclear transport (Fig. 
ZE), but stimulated only marginal transcriptional activation 
a t  100 nM (Fig. 6). Hydroxyflutamide acted, therefore, as a 
pure  antiandrogen as proposed previously (9). 
The antiandrogens, flutamide, hydroxyflutamide, and cy- 
proterone acetate, were tested for their ability to inhibit 
androgen-induced CAT activity. As shown in Fig.  7, flutamide 
(500 nM) caused about  a 50% inhibition of R1881- (0.05 nM) 
induced CAT activity. This inhibitory effect may result in 
part from limited metabolic conversion of flutamide to hy- 
droxyflutamide as previously suggested from in uiuo studies 
(4-7). Hydroxyflutamide- (500 nM) inhibited R1881 (0.05 nM) 
induced CAT activity by approximately 90%, while alone, it 
increased CAT activity only slightly higher than background 
(Fig. 7). The inhibitory  activity of cyproterone acetate a t  10 
nM was about 50%. Higher concentrations of cyproterone 
acetate showed strong agonist  activity as noted above. Thus 
all  three antiandrogens  inhibited androgen-induced CAT ac- 
tivity to different degrees, the most effective being hydroxy- 
flutamide. 
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FIG. I .  Inhibition of androgen-induced transcriptional CAT 
activity by antiandrogens. CV1  cells transfected  with  either  parent 
vector (P5, lunes I and 2) or  the full-length  AR  expression plasmid 
were placed in 0.2% serum and not further treated (no hormone 
addition)  or  treated  with 0.05 M R1881 in  the presence and  absence 
of 500 nM flutamide  or hydroxyflutamide or  10  and 500 nM cyproter- 
one acetate as indicated. Some samples as indicated received only 
antiandrogen  treatment. The acetylated  forms of [“CJchloramphen- 
icol were separated by thin layer chromatography  and  the  plate was 
exposed to  x-ray film. The  spots were quantitated by elution of the 
silica plate  and radioactive scintillation  counting  and  are  shown as 
fold induction  in  the bar graph below. 
DISCUSSION 
The AR has high binding  affinity and specificity for the 
biologically active androgens, but only at  low steroid concen- 
trations. Lack of AR steroid binding specificity at  elevated 
steroid  concentrations  characterizes  both t e endogenous (34) 
and  transiently expressed recombinant receptor as demon- 
strated in this report and shown previously for a truncated 
form of the expressed AR (37). A question addressed in the 
present study was whether the AR undergoes functional ac- 
tivation when bound to nonandrogenic hormones for which it 
has low to moderate binding affinity. The studies indicate 
that  the antiandrogens,  cyproterone  acetate, estrogen, proges- 
terone, and RU486, not only promote nuclear transport,  but 
enhance transcriptional activation by AR. In contrast, only 
high affinity androgen binding stabilized the AR protein, 
slowing its rate of degradation and making it appear that 
androgen induced AR phosphorylation. Of the steroids and 
antihormones tested in the transient cotransfection assay, 
hydroxyflutamide had properties closest to a true  antiandro- 
gen since it inhibited androgen-induced transcriptional  acti- 
vation and did not significantly enhance AR-mediated tran- 
scriptional activation. 
AR nuclear transport in transiently transfected COS cells 
was shown previously to be androgen-dependent (20). In  the 
absence of hormone  addition, AR displays a  striking  punctate 
perinuclear distribution in the cytoplasm, while androgen 
addition causes strong nuclear immunostaining. The perinu- 
clear cytoplasmic localization of  AR in  the absence of andro- 
gen was not evident, however, with the endogenous receptor 
following androgen withdrawal by castration for reasons not 
fully understood (30). In tissue  sections of rat ventral  prostate, 
nuclear staining is strong  in the  intact animal but castration 
causes loss of immunoreactivity. It is conceivable that  the 
rapid  turnover of the AR protein  in the absence of androgen 
as described in this study, albeit in transfected COS cells, 
contributes to  the loss of immunstaining  in  ventral  prostate 
tissue sections following castration. Steroids and antihor- 
mones that bind AR with moderate affinity and stimulate 
CAT activity at  elevated hormone concentrations also pro- 
mote AR nuclear transport  in transfected COS  cells.  However, 
hydroxyflutamide caused strong nuclear immunostaining  but 
failed to induce AR-mediated transactivation. It is clear, 
therefore, that nuclear localization per se is necessary but not 
sufficient for transcriptional activation, as suggested earlier 
in  studies with truncated  mutant forms of AR. AR deletion 
mutants lacking the NH2-terminal domain were constitutively 
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nuclear yet lacked gene transcriptional  activity  due to deletion 
of sequences critical for AR function (20). 
The cell systems (CV1 and COS monkey kidney cells) used 
in formulating conclusions concerning hormone specificity of 
nuclear transport, transcriptional activity, phosphorylation, 
and receptor turnover, could be considered somewhat artificial 
since they do not express AR endogenously and may be 
deficient in certain  transcription  factors required to promote 
hormone-specific gene activation. However, many of the re- 
sults of these transient transfection  studies  parallel  earlier 
observations in uiuo. For example, it was recognized that 
progestational steroids promote AR-mediated gene activation 
in uiuo and stimulate growth of the male reproductive tract 
and virilization of the female fetus (38-40). Furthermore, 
progestins potentiate nuclear uptake of  AR in uiuo in mouse 
kidney (41). Cyproterone acetate, a progestational steroid 
(42), has  not been considered a true antiandrogen because it 
has  both agonist and antagonist activities in vivo (40, 43). 
The present  study  supports these observations in that cypro- 
terone acetate acts  as  an androgenic agonist in AR-mediated 
transcriptional activation as determined by CAT assay at  
elevated steroid  concentrations (100 nM), but  as  an androgen 
antagonist at  a lower hormone concentration (10 nM). On the 
other hand, cyproterone acetate at  elevated concentrations 
was antagonistic to androgen-induced AR stabilization. 
The parallel between endogenous and  transiently expressed 
AR extends to  the activity of the nonsteroidal  antiandrogen, 
hydroxyflutamide. Hydroxyflutamide, unlike cyproterone ace- 
tate, lacks agonist activity in vivo yet has antiandrogenic 
activity nearly equivalent to  that of cyproterone acetate (2). 
Hydroxyflutamide has therefore been considered a  pure an- 
tiandrogen (2, 3). It maintains these  characteristics  in the in 
vitro system described here since it did not enhance CAT 
activity, yet inhibited androgen induction of AR transcrip- 
tional activation. Since hydroxyflutamide binds AR with mod- 
erate affinity and induces nuclear transport,  its binding may 
impose an altered receptor conformation not conducive to 
gene activation as suggested for RU486 binding to  the gluco- 
corticoid receptor (18). 
It is intriguing to note that  the androgen-dependent  human 
prostate cancer cell line, LNCaP, responds to hydroxyflutam- 
ide as well as estradiol and progesterone with an increase in 
cell proliferation (44,45).  Estradiol and progesterone binding 
was inhibited by androgen  indicating that  their effects were 
mediated by the AR (44). In  the  LNCaP cell line, testosterone, 
R1881, and cyproterone acetate each induced AR mRNA 
down-regulation. However, estrogen failed to down-regulate 
AR mRNA both in  the  LNCaP cell line and in normal rat 
prostate (46). Thus, while estrogen had agonist activity  in the 
induction of AR gene activation, it did not mimic androgen 
effects on AR mRNA. The AR gene in LNCaP cells contains 
a single base mutation that changes amino acid residue 877 
from threonine to alanine (47). In cotransfection studies with 
the reconstructed mutant AR, a striking increase in  transcrip- 
tional activity was observed with hydroxyflutamide suggesting 
that  an alteration of one  amino acid within the steroid-binding 
domain allowed hydroxyflutamide to acquire agonist  activity 
(48). The  LNCaP AR also increased transcriptional  activation 
in response to progesterone and cyproterone acetate (49). 
Antihormone binding to steroid receptors can initiate early 
steps in gene activation, i.e. receptor entry  to  the nucleus and 
DNA binding. Progesterone receptor binding of RU486 pro- 
motes interaction with response element DNA but fails to 
stimulate transcription (15). Interestingly, although RU486 
is a true antagonist for the glucocorticoid receptor, it had 
agonist activity when bound to AR. Furthermore, of those 
tested, RU486 was the only steroid that caused an increase in 
AR phosphorylation that was not offset by a concomitant 
increase in receptor protein  due to stabilization. It was re- 
ported previously that RU486 binds endogenous AR of rat 
prostate (50) and  inhibits androgen-induced prostate growth 
(51). Antagonistic effects of RU486 mediated through the AR 
were also suggested when it blocked androgen inhibition of 
prolactin release in uiuo (52). 
Another mechanism proposed for the inability of antihor- 
mones to promote receptor-mediated gene transcription in- 
volves stabilization of oligomeric receptor forms. It was re- 
ported that RU486 bound to  the glucocorticoid receptor in 
uiuo stabilizes the 8 S receptor form which does not enter  the 
nucleus (17) or  interact with DNA (53,54). The results of the 
present  study do not support  a  similar effect on AR. 
A question remaining from these  studies is  the role of AR 
phosphorylation in transcriptional activation by  AR. The 
ability of  AR to induce transcriptional activity in response to 
steroids or antiandrogens with few exceptions paralleled rel- 
ative binding specificity and affinity. The  apparent effect of 
androgen on AR phosphorylation was nullified when receptor 
stability was considered. Androgen increased the amount of 
AR phosphorylation simply by  slowing the  rate of degradation 
of the AR protein. AR stabilization by androgen was observed 
previously in binding studies on tissue cytosols (34). More- 
over, in a ductus deferens smooth muscle tumor cell line, 
endogenous AR stabilization increased about 2-fold with an- 
drogen, from t1/2 3.1 h without androgen to tIl2 6.6 h with 
R1881 (55). The mechanism of receptor stabilization by an- 
drogen is not known but  the striking specificity for androgen 
suggests it may be closely linked with receptor functional 
activity. Although other groups have reported on steroid- 
induced phosphorylation of AR (25) and  the glucocorticoid 
and progesterone receptors (21-24), no androgen-dependent 
enhancement of recombinant AR phosphorylation was de- 
tected  in the present study. While the AR is clearly a phos- 
phoprotein, the specific role of phosphorylation in receptor 
function is unclear. AR sites of phosphorylation are  currently 
being mapped, and  it is conceivable that androgen binding 
may increase phosphorylation of a single site not detectable 
in our assay system. 
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